Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

Also called NCT02354235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 138 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02354235
Other papers using this trial's data
  • Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial Diabetes, obesity & metabolism, 2017-06 DOI, PubMed 28177187, PMC5484989 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02354235. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2018-08-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Teneligliptin
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02354235
Content hash
e5fe28073ac486285fb7b5136b21abede22c23dd0a7ff06fbc319d3f5f087580